Cambridge Confidence in Concepts: translating pathophysiological insights for patient benefit

Lead Research Organisation: University of Cambridge

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50
 
Description (SilkFUSION) - Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bio-inks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research
Amount € 2,998,500 (EUR)
Funding ID 767309 
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 11/2017 
End 10/2021
 
Description BBSRC DTP PhD studentship
Amount £120,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 05/2017 
 
Description BHF Translational Award
Amount £248,018 (GBP)
Funding ID TG/15/4/31891 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2016 
End 03/2017
 
Description Biomedical Catalyst: DPFS. MICA: A Developmental Trial of Personalised Medicine for Repurposing Zibotentan, a Selective Endothelin A Receptor Blocker, in Microvascular Angina
Amount £3,003,000 (GBP)
Funding ID MR/S018905/1 
Organisation MRC Biomedical Catalyst Developmental Pathway Funding Scheme (DPFS) 
Sector Academic/University
Country United Kingdom
Start  
 
Description Blood and Transplant Grant
Amount £900,000 (GBP)
Organisation NHS England 
Sector Public
Country United Kingdom
Start 09/2015 
End 10/2020
 
Description COMMIT - Continuous Online Metabolite Monitoring.
Amount £1,137,648 (GBP)
Funding ID NIHR200986 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 03/2020 
End 03/2023
 
Description CRUK Multidisciplinary Project award
Amount £483,000 (GBP)
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description CRUK Pioneer award
Amount £200,000 (GBP)
Organisation Cancer Research UK 
Department CRUK Centre for Cancer Therapeutics
Sector Private
Country United Kingdom
Start  
 
Description Cell death by RNA trans-splicing as a gene therapy for hepatocellular carcinoma
Amount £193,312 (GBP)
Funding ID RG90696 
Organisation Cancer Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
 
Description CiC-Development of a Transcatheter Mitral Repair System for patients with Mitral Regurgitation
Amount £69,978 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 02/2017 
End 11/2017
 
Description Clinical Research Training Fellowship
Amount £116,678 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2016 
End 08/2019
 
Description Combined biomechanical modelling and imaging to predict human atherosclerotic plaque rupture and growth
Amount £109,776 (GBP)
Funding ID RG2638 
Organisation Heart Research UK 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2015 
End 12/2016
 
Description Deciphering key switches of platelet formation
Amount £20,000 (GBP)
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2017 
End 07/2018
 
Description Development of 3D finite element analysis and imaging to predict human atherosclerotic plaque instability
Amount £249,185 (GBP)
Funding ID PG/18/14/33562 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2018 
End 03/2021
 
Description Gates Scholarship PPR project
Amount £130,000 (GBP)
Organisation Serth and Gates Charitable Trust 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Howe & Nisbet R5.6 - Building collaborations to study parasitic diseases of African livestock
Amount £5,166 (GBP)
Organisation United Kingdom Research and Innovation 
Department Global Challenges Research Fund
Sector Public
Country United Kingdom
Start  
 
Description Howe & Nisbet R5.6 - Plastid Preview 2017
Amount £1,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Department Networks in Industrial Biotechnology and Bioenergy (NIBB)
Sector Academic/University
Country United Kingdom
Start  
 
Description Howe & Nisbet R5.6 - Plastid Preview 2017
Amount £2,500 (GBP)
Organisation Gatsby Charitable Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Howe & Nisbet R5.6 - Plastid Preview 2017
Amount £1,500 (GBP)
Organisation Company of Biologists 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Howe & Nisbet R5.6 - Plastid Preview 2017
Amount £500 (GBP)
Organisation Company of Biologists 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Mechanistic study of the effect of ET-1 SNPs in Coronary Microvascular Disease (PRIZE ET Sub-Study)
Amount £208,976 (GBP)
Organisation J P Moulton Charitable Foundation 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2020 
End 01/2023
 
Description NIHR i4i
Amount £537,000 (GBP)
Funding ID II-C5-0715-20005 
Organisation National Institute for Health Research 
Department NIHR i4i Invention for Innovation (i4i) Programme
Sector Public
Country United Kingdom
Start 03/2016 
End 04/2019
 
Description NIHR i4i Challenge Award, Development of microdialysis online sensor technology for use in critical care of acute brain trauma patients
Amount £536,627 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 09/2016 
End 10/2019
 
Description NIHR i4i Product Development Award - COMMIT - Continuous Online Metabolite Monitoring
Amount £1,137,648 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 03/2020 
End 03/2023
 
Description PhD studentship
Amount £128,000 (GBP)
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start  
 
Description Pluripotent Stem and Engineered Cell Platform
Amount £3,000,000 (GBP)
Organisation UK Regenerative Medicine Platform 
Sector Academic/University
Country United Kingdom
Start 05/2018 
End 04/2023
 
Description Production of HLA-null universal platelets from GMP banked human pluripotent stem cell lines
Amount £208,259 (GBP)
Funding ID MR/P007813/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2016 
End 09/2017
 
Description SBC Grant
Amount £154,000 (GBP)
Organisation Higher Education Funding Council for England 
Sector Public
Country United Kingdom
Start  
 
Description SilkFusion: Genetically engineered human pluripotent stem cells, functionalized silk-fibroin platforms and bioinks: a novel solution for large-scale ex-vivo platelet production, transfusion and drug research
Amount € 3,200,000 (EUR)
Organisation European Commission 
Sector Public
Country European Union (EU)
Start 11/2017 
End 12/2021
 
Description Supercharging Platelets to Prevent Blood Loss after Trauma and Regenerate Hearts after Heart Attacks
Amount £59,450 (GBP)
Funding ID M724 
Organisation Rosetrees Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 10/2020
 
Description Targeting Theileria: Identification of novel drug targets against East Coast Fever.
Amount £19,852 (GBP)
Organisation Cambridge-Africa Alborada Trust 
Sector Academic/University
Country United Kingdom
Start  
 
Description Targeting latent human cytomegalovirus (HCMV) infection by novel chemo and immunotherapeutic strategies to prevent virus reactivation in transplant settings
Amount £448,865 (GBP)
Organisation GlaxoSmithKline (GSK) 
Sector Private
Country Global
Start 07/2017 
End 07/2020
 
Description The RIVER Trial
Amount £1,000,007 (GBP)
Funding ID MR/L00528X/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description To support research on PPR protein in Toxoplasma gondii.
Amount £10,000 (GBP)
Organisation University of Cambridge 
Department Returning Carers Scheme
Sector Academic/University
Country United Kingdom
Start  
 
Description Transitioning in vitro platelet production to GMP
Amount £100,000 (GBP)
Organisation Defence Science & Technology Laboratory (DSTL) 
Sector Public
Country United Kingdom
Start 01/2020 
End 01/2021
 
Description Understanding human cytomegalovirus latency as a means to target the latent reservoir
Amount £1,864,411 (GBP)
Funding ID MR/S00081X/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 11/2018 
End 10/2023
 
Description Understanding human cytomegalovirus latency as a means to target the latent reservoir
Amount £2,500,000 (GBP)
Funding ID (MR/S00081X/1) 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description Universal cells to overcome HLA barriers in regenerative medicine
Amount £1,000,000 (GBP)
Organisation UK Regenerative Medicine Platform 
Sector Academic/University
Country United Kingdom
Start 01/2019 
End 01/2022
 
Description a University HEFCE grant
Amount £204,392 (GBP)
Funding ID RG74090 
Organisation NIHR/HEFCE Higher Education Fund for England 
Sector Public
Country United Kingdom
Start 01/2016 
End 03/2017
 
Description an electron cryo-microscopy resource for macromolecular structure determination in the University of Cambridge
Amount £1,000,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 06/2016 
End 12/2021
 
Description titan krios cryoem
Amount £3,000,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2017 
End 02/2022
 
Description visualising transport dynamics of transmembrane pumps
Amount £1,954,530 (GBP)
Organisation European Commission H2020 
Sector Public
Country Belgium
Start 08/2017 
End 08/2022
 
Description BHF translational award workshop 
Organisation AstraZeneca
Department MedImmune
Country United Kingdom 
Sector Private 
PI Contribution Cyclic Peptide agonists • Discovery of Cyclic Peptide agonists with improved pharmacokinetic and pharmacodynamic properties • Sosei Heptares' Opportunities in Receptor Biology for Industrial Translation (Orbit) Project Grant will translate discoveries during the next three years in animal models of PAH • Evaluation and Option agreement with Sosei Heptares. Company will evaluate peptides discovered by Glen and Davenport • Collaboration between Davenport and Glen continuing on improving PK and PD properties of MM07. • New collaboration on different peptides with Sosei Heptares
Collaborator Contribution Ongoing research with Sosei Heptares, tested over 50 peptide analogues and lead compounds identified following in vivo testing. b) Biased peptide apelin agonists with long plasma half-lives by conjugation with human serum binding domains • Agonists conjugated to AlbudAb antibody to increase plasma half-life (GSK Innovation Funding Opportunity) to link apelin to antibodies to extend the plasma half-life for up to twenty days. This technology is applicable to other peptide ligands which frequently fulfil properties of high affinity and selectivity but plasma half-lives are usually a few minutes. • See below • EMI: Relaxin (AZ) Define study will commence in January 2020 to determine the action of relaxin in human forearm studies c) Apelin receptor antagonists for the treatment of brain cancer, glioblastoma • With collaborators we have discovered our (Glen/Davenport) antagonists have efficacy to block the action of endogenous apelin released from endothelial cells to reduce tumour size in the glioblastoma model of human glioblastoma cells in mouse brain.
Impact regular meetings (each fortnight) and presentations with staff from Sosei Regular meetings with staff from AZ BHF translational award workshop Research carried out by my research group in industry labs (Sosei Heptares, AZ, Takeda) • GSK Innovation Funding Opportunity RG77409 • Sosei Heptares RG86507, RG87431 • AZ RG91869
Start Year 2019
 
Description BHF translational award workshop 
Organisation Heptares Therapeutics Ltd
Country United Kingdom 
Sector Private 
PI Contribution Cyclic Peptide agonists • Discovery of Cyclic Peptide agonists with improved pharmacokinetic and pharmacodynamic properties • Sosei Heptares' Opportunities in Receptor Biology for Industrial Translation (Orbit) Project Grant will translate discoveries during the next three years in animal models of PAH • Evaluation and Option agreement with Sosei Heptares. Company will evaluate peptides discovered by Glen and Davenport • Collaboration between Davenport and Glen continuing on improving PK and PD properties of MM07. • New collaboration on different peptides with Sosei Heptares
Collaborator Contribution Ongoing research with Sosei Heptares, tested over 50 peptide analogues and lead compounds identified following in vivo testing. b) Biased peptide apelin agonists with long plasma half-lives by conjugation with human serum binding domains • Agonists conjugated to AlbudAb antibody to increase plasma half-life (GSK Innovation Funding Opportunity) to link apelin to antibodies to extend the plasma half-life for up to twenty days. This technology is applicable to other peptide ligands which frequently fulfil properties of high affinity and selectivity but plasma half-lives are usually a few minutes. • See below • EMI: Relaxin (AZ) Define study will commence in January 2020 to determine the action of relaxin in human forearm studies c) Apelin receptor antagonists for the treatment of brain cancer, glioblastoma • With collaborators we have discovered our (Glen/Davenport) antagonists have efficacy to block the action of endogenous apelin released from endothelial cells to reduce tumour size in the glioblastoma model of human glioblastoma cells in mouse brain.
Impact regular meetings (each fortnight) and presentations with staff from Sosei Regular meetings with staff from AZ BHF translational award workshop Research carried out by my research group in industry labs (Sosei Heptares, AZ, Takeda) • GSK Innovation Funding Opportunity RG77409 • Sosei Heptares RG86507, RG87431 • AZ RG91869
Start Year 2019
 
Description BHF translational award workshop 
Organisation Sosei Group
Country Japan 
Sector Private 
PI Contribution Cyclic Peptide agonists • Discovery of Cyclic Peptide agonists with improved pharmacokinetic and pharmacodynamic properties • Sosei Heptares' Opportunities in Receptor Biology for Industrial Translation (Orbit) Project Grant will translate discoveries during the next three years in animal models of PAH • Evaluation and Option agreement with Sosei Heptares. Company will evaluate peptides discovered by Glen and Davenport • Collaboration between Davenport and Glen continuing on improving PK and PD properties of MM07. • New collaboration on different peptides with Sosei Heptares
Collaborator Contribution Ongoing research with Sosei Heptares, tested over 50 peptide analogues and lead compounds identified following in vivo testing. b) Biased peptide apelin agonists with long plasma half-lives by conjugation with human serum binding domains • Agonists conjugated to AlbudAb antibody to increase plasma half-life (GSK Innovation Funding Opportunity) to link apelin to antibodies to extend the plasma half-life for up to twenty days. This technology is applicable to other peptide ligands which frequently fulfil properties of high affinity and selectivity but plasma half-lives are usually a few minutes. • See below • EMI: Relaxin (AZ) Define study will commence in January 2020 to determine the action of relaxin in human forearm studies c) Apelin receptor antagonists for the treatment of brain cancer, glioblastoma • With collaborators we have discovered our (Glen/Davenport) antagonists have efficacy to block the action of endogenous apelin released from endothelial cells to reduce tumour size in the glioblastoma model of human glioblastoma cells in mouse brain.
Impact regular meetings (each fortnight) and presentations with staff from Sosei Regular meetings with staff from AZ BHF translational award workshop Research carried out by my research group in industry labs (Sosei Heptares, AZ, Takeda) • GSK Innovation Funding Opportunity RG77409 • Sosei Heptares RG86507, RG87431 • AZ RG91869
Start Year 2019
 
Description BHF translational award workshop 
Organisation Takeda Cambridge Ltd
Country United Kingdom 
Sector Private 
PI Contribution Cyclic Peptide agonists • Discovery of Cyclic Peptide agonists with improved pharmacokinetic and pharmacodynamic properties • Sosei Heptares' Opportunities in Receptor Biology for Industrial Translation (Orbit) Project Grant will translate discoveries during the next three years in animal models of PAH • Evaluation and Option agreement with Sosei Heptares. Company will evaluate peptides discovered by Glen and Davenport • Collaboration between Davenport and Glen continuing on improving PK and PD properties of MM07. • New collaboration on different peptides with Sosei Heptares
Collaborator Contribution Ongoing research with Sosei Heptares, tested over 50 peptide analogues and lead compounds identified following in vivo testing. b) Biased peptide apelin agonists with long plasma half-lives by conjugation with human serum binding domains • Agonists conjugated to AlbudAb antibody to increase plasma half-life (GSK Innovation Funding Opportunity) to link apelin to antibodies to extend the plasma half-life for up to twenty days. This technology is applicable to other peptide ligands which frequently fulfil properties of high affinity and selectivity but plasma half-lives are usually a few minutes. • See below • EMI: Relaxin (AZ) Define study will commence in January 2020 to determine the action of relaxin in human forearm studies c) Apelin receptor antagonists for the treatment of brain cancer, glioblastoma • With collaborators we have discovered our (Glen/Davenport) antagonists have efficacy to block the action of endogenous apelin released from endothelial cells to reduce tumour size in the glioblastoma model of human glioblastoma cells in mouse brain.
Impact regular meetings (each fortnight) and presentations with staff from Sosei Regular meetings with staff from AZ BHF translational award workshop Research carried out by my research group in industry labs (Sosei Heptares, AZ, Takeda) • GSK Innovation Funding Opportunity RG77409 • Sosei Heptares RG86507, RG87431 • AZ RG91869
Start Year 2019
 
Description Collaborative support in the form of a USB snapshot camera package 
Organisation XIMEA GmbH
Country Germany 
Sector Private 
PI Contribution Further development of a novel video-rate near-infrared endoscope
Collaborator Contribution Collaborative support of the research
Impact Publications: 1) doi: 10.1117/1.JBO.21.8.084001 ; 2) https://doi.org/10.1088/2040-8986/aa6176
Start Year 2015
 
Description Funding of RIVER 
Organisation Merck
Department Merck Sharp and Dohme Ltd
Country United Kingdom 
Sector Private 
PI Contribution - The RIVER trial (collaborations with GSK and MSD). Additional funding for HIV latency research to the Lever through MRC fellowships and grants from the Academy of Medical Sciences and Evelyn Trust: £614,567. (added in Jan 2020) - RIVER trial completed and accepted for publication in Lancet - The CHERUB collaboration aimed at HIV cure supported development of a virus reactivation assay by Wills and Lever, which was a crucially important component of the successful application by CHERUB for MRC DCS funding for a clinical trial that provided £1.7m to support 'RIVER', a randomized clinical study. It was crucial in the validation of viral remission in the recently reported second case of HIV 'cure' (Gupta et al 2019; HIV-1 remission following CCR5?32/?32 haematopoietic stem-cell transplantation; Nature 568, 244-248).
Collaborator Contribution Funding of RIVER: RIVER was funded by the Medical Research Council (Grant ref MR/L00528X/1) in collaboration with support from industry partners. Raltegravir and Vorinostat are manufactured by Merck Sharp and Dohme (MSD). MSD agreed to supply the study drugs free of charge for participants participating in the study. The manufacture of ChAdV63.HIVconsv and MVA.HIVconsv vaccines and all pre-clinical and clinical work to date for these vaccines have been provided free of charge to the RIVER study by Lucy Dorrell and Tomáš Hanke of the University of Oxford utilising their existing MRC grants. GSK own the ChAd vector and have reviewed the RIVER protocol and have approved the use of the ChAdV63.HIVconsv. in the RIVER study. RIVER was run by 'CHERUB', a UK collaboration of five universities pooling their expertise to develop an HIV cure. CHERUB is supported by the National Institute for Health Research and brings together HIV researchers at Imperial College London, the University of Oxford, the University of Cambridge, Medical Research Council Clinical Trials Unit at UCL, and King's College London. RIVER was funded by the Medical Research Council, UK and the industry partners, MSD and GSK. The RIVER trial has now completed
Impact Funding of RIVER: RIVER was funded by the Medical Research Council (Grant ref MR/L00528X/1) in collaboration with support from industry partners. Raltegravir and Vorinostat are manufactured by Merck Sharp and Dohme (MSD). MSD agreed to supply the study drugs free of charge for participants participating in the study. The manufacture of ChAdV63.HIVconsv and MVA.HIVconsv vaccines and all pre-clinical and clinical work to date for these vaccines have been provided free of charge to the RIVER study by Lucy Dorrell and Tomáš Hanke of the University of Oxford utilising their existing MRC grants. GSK own the ChAd vector and have reviewed the RIVER protocol and have approved the use of the ChAdV63.HIVconsv. in the RIVER study. RIVER was run by 'CHERUB', a UK collaboration of five universities pooling their expertise to develop an HIV cure. CHERUB is supported by the National Institute for Health Research and brings together HIV researchers at Imperial College London, the University of Oxford, the University of Cambridge, Medical Research Council Clinical Trials Unit at UCL, and King's College London. RIVER was funded by the Medical Research Council, UK and the industry partners, MSD and GSK. The RIVER trial has now completed and been published
Start Year 2015
 
Title Compounds for use as apelin receptor antagonists 
Description Davenport, A.P., Maguire, J.J. Glen, R.C., (2019) United Kingdom Patent Application 1805675.4 Compounds for use as apelin receptor antagonists(International Patent Application No. PCT/GB2019/050992 
IP Reference 201980033458.8 ; A+I ref: P032639CN; [AI-WS.FID1024505] 
Protection Patent granted
Year Protection Granted 2019
Licensed No
Impact Patent holders (Davenport, Maguire Glen) in 2020 assigned above patent to University of Cambridge (via Cambridge Enterprise) to enable grant sponsor Cancer Research UK to progress the international patents. The following are now held by Cambridge Enterprise: Chinese Patent Application No. 201980033458.8 ; A+I ref: P032639CN; [AI-WS.FID1024505] United States Patent Application No. 17/044923; A+I ref: P032639US; [AI-WS.FID1024529] European Patent Application No. 19717580.5; A+I ref: P032639EP; [AI-WS.FID1024517]
 
Title Compounds for use as apelin receptor antagonists 
Description The present inventors have discovered a number of linear peptides which are capable of acting as competitive apelin antagonists which may be useful in the treatment of conditions such as cancer.. 
IP Reference PCT/GB2019/050992 
Protection Patent application published
Year Protection Granted 2019
Licensed Commercial In Confidence
Impact These include compounds that are more potent antagonists than the known macrocyclic apelin antagonist MM54 and have an improved pharmacology profile.
 
Title DEVICE FOR INSERTION INTO HUMAN OR ANIMAL BODY AND ASSOCIATED METHODS 
Description An implant device for insertion in a human or animal body comprises a frame, wherein at least a portion of the frame is capable of reversibly transitioning between a solid state rigid mode and a liquid state flexible mode, thereby allowing the device to change its shape. 
IP Reference WO2016181138 
Protection Patent application published
Year Protection Granted 2016
Licensed Commercial In Confidence
Impact Not yet
 
Title Trans splicing technology 
Description Trans splicing technology being patented by Cambridge Enterprise and licensed to our spinout company 
IP Reference  
Protection Patent granted
Year Protection Granted
Licensed Yes
Impact The creation of a spin out company, Spliceor Therapeutics has been achieved.
 
Title - The CHERUB collaboration 
Description - The CHERUB collaboration aimed at HIV cure supported development of a virus reactivation assay by Wills and Lever, which was a crucially important component of the successful application by CHERUB for MRC DCS funding for a clinical trial that provided £1.7m to support 'RIVER', a randomized clinical study. It was crucial in the validation of viral remission in the recently reported second case of HIV 'cure' (Gupta et al 2019; HIV-1 remission following CCR5?32/?32 haematopoietic stem-cell transplantation; Nature 568, 244-248). Funding of RIVER: RIVER was funded by the Medical Research Council (Grant ref MR/L00528X/1) in collaboration with support from industry partners. Raltegravir and Vorinostat are manufactured by Merck Sharp and Dohme (MSD). MSD agreed to supply the study drugs free of charge for participants participating in the study. The manufacture of ChAdV63.HIVconsv and MVA.HIVconsv vaccines and all pre-clinical and clinical work to date for these vaccines have been provided free of charge to the RIVER study by Lucy Dorrell and Tomáš Hanke of the University of Oxford utilising their existing MRC grants. GSK own the ChAd vector and have reviewed the RIVER protocol and have approved the use of the ChAdV63.HIVconsv. in the RIVER study. RIVER was run by 'CHERUB', a UK collaboration of five universities pooling their expertise to develop an HIV cure. CHERUB is supported by the National Institute for Health Research and brings together HIV researchers at Imperial College London, the University of Oxford, the University of Cambridge, Medical Research Council Clinical Trials Unit at UCL, and King's College London. RIVER was funded by the Medical Research Council, UK and the industry partners, MSD and GSK. 
Type Therapeutic Intervention - Vaccines
Year Development Stage Completed 2019
Development Status Closed
Impact A panel of 3'exon replacement constructs have been cloned into lentiviral gene transfer vectors for subsequent lentiviral vector production and validation of RNA trans-splicing and killing of HIV-infected cells of the immune system. RNA trans-splicing lentiviral vectors have been produced with detectable lentiviral protein in viral supernatants shown by ELISA. RNA transgene expression is being investigated in transduction experiments, and in some constructs RNA trans-gene expression has been confirmed in a preliminary experiment. Vector transfer and successful trans splicing have been demonstrated with a significant specific killing of HIV infected cells Optimisation of vector production has been achieved and more selective killing of HIV infected versus non infected cells has been seen. The work is now being targeted to attempt to kill cells containing reactivated latent HIV 
 
Description 'Imaging your Insides: Stroke and Heart Attack Prevention' 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Dr Teng participated in Homerton 250-- Future visions of healthcare, Homerton College, by giving 'Imaging your Insides: Stroke and Heart Attack Prevention' at 10 Feb 2018 to the general audience. Dr Teng introduced vascular imaging and its application in stroke and heart attack prevention to the audiences from the local community.
Year(s) Of Engagement Activity 2018
 
Description "Producing Platelets In Vitro: The Challenges of MK Production and Platelet Release or Clinical Use: Numbers and Quality" 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The focus of this meeting is to bring together our understanding of the processes involved in the development of the megakaryocyte and platelet cell lineage and how these cells can contribute to health and disease.
Year(s) Of Engagement Activity 2019
 
Description 'From corals to malaria' 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Talk for Stephen Perse Foundation Sixth Form, Cambridge
Year(s) Of Engagement Activity 2019
 
Description - CRUK Innovation Summit 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Ania Piskorz presented at the summit highlighting her entrepreneurship activities involving our recently created startup Tailor Bio and our support from the MRC through the CiC award. This activity created awareness of Ania's science in a commercial setting and has expanded our network and opportunities to commercialise the output of this study.
Year(s) Of Engagement Activity 2019
URL https://www.cancerresearchuk.org/funding-for-researchers/research-events-and-conferences/innovation-...
 
Description A novel split mode TFBAR device for quantitative measurements of prostate specific antigen in a small sample of whole blood 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Media (as a channel to the public)
Results and Impact Appearance on
- BBC Look East
- BBC Breakfast
Year(s) Of Engagement Activity 2020
 
Description Abstract selected for short-talk at Single Cell Biology Conference (Wellcome Sanger Institute) virtual edition. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Abstract selected for short talk Virtual edition presented by Carys Johnson, PhD Student at the Wellcome Sanger Institute.
Year(s) Of Engagement Activity 2020
 
Description American Peptide Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact The student presented her work at a conference in the form of a poster. She won a prize for her poster presentation and in light of that was invited to write a review article on her field of study. This article was submitted Jan 2020.
Year(s) Of Engagement Activity 2019
 
Description Artemis-A - School visits (e.g Landmark International School, Fulbourn; School visit (Soham Village College, Soham) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact We have presented the Artemis-A and talked about the project in four secondary schools in the area (Cambridge, Ely).
These engagement activities were integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project
Year(s) Of Engagement Activity 2019
 
Description Artemis-R 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact this is a network of researchers and practitioners who were interested in supporting mental health in schools.
These engagement activities were integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project.
Year(s) Of Engagement Activity 2020
 
Description BPS-MPGPCR 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact This was a research focussed meeting attended by GPCR researchers and industry. This meeting was to disseminate scientific finds. It resulted in us initiated a strong collaboration with the Monash group lead by Sexton and Wootten.
Year(s) Of Engagement Activity 2018
 
Description Biochemistry' 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Schools
Results and Impact Laboratory practical and introductory lecture for 42 high school students visiting Cambridge from state (i.e. government) schools in the South West of England
Year(s) Of Engagement Activity 2019
 
Description British Society for Cardiovascular Research, Coronavirus and the cardiovascular system 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact BSCR reported there were 174 international attendees with a recording made available on the BSCR webpage together with a meeting report including the question and answer session. Positive feedback means BSCR will repeat the format next year.
Year(s) Of Engagement Activity 2020
URL https://bscr.org/event/bscr-autumn-2020-ol/
 
Description CLIRSPEC Summer School 2019 - Mid-infrared chemical and Biochemical sensors 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Undergraduate students
Results and Impact Farah Alimagham attended a Summer School on Clinical Spectroscopy - CLIRSPEC Summer School 2019 - approx. 50 attendees, international, 2th- 5th July 2019, Low Wood Bay, Windermere, UK - and gave a short (approx. 10 min) talk entitled "Mid-infrared chemical and Biochemical sensors", not directly mentioning our sensor due to IP issues (and the fact that at the time of the Summer School we were still filling for the patent), but she mentioned continuous monitoring using mid-IR and also her porous silicon on fibre-work which we had published.
Year(s) Of Engagement Activity 2019
 
Description COVID-19 treatments called into question 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Media (as a channel to the public)
Results and Impact There was optimism when UK Health Secretary Matt Hancock announced that a drug called remdesivir, which appears to shorten recovery time by about four days for people with Covid 19, is being made available on the NHS. The Health Secretary said it was probably the biggest step forward in the treatment of seriously ill patients since the crisis began. On the other hand it turns out a drug being touted, and taken, by President Trump isn't reliably good after all. The effect of hydroxychloroquine has been called into question after an analysis by American researchers who say it might even make things worse. While their study has limitations - particularly the fact that they looked at the drugs' effects at very high dose - the World Health Organisation has suspended trials of hydroxychloroquine, along with those of another chemically similar drug called chloroquine. The research has been published in the Lancet medical journal, and Phil Sansom has been discussing the drugs with Cambridge University pharmacologist, Anthony Davenport...
Year(s) Of Engagement Activity 2020
URL https://www.thenakedscientists.com/articles/interviews/covid-19-treatments-called-question
 
Description CRUK Single Cell Workshop in Southampton 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Here we presented some preliminary results on using our protocol to explore ongoing chromosomal instability in ovarian cancer cell lines. The presentation was well received and provided validation of our approach for research use.
Year(s) Of Engagement Activity 2019
URL https://www.eventbrite.co.uk/e/single-cell-analysis-in-cancer-a-workshop-tickets-64716482742?utm_cam...
 
Description Cambridge-AstraZeneca Symposium 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact AstraZeneca and University of Cambridge are holding a joint virtual Science Symposium, with sessions including disease models, pre-clinical and clinical research,data science and the use of AI in medicine. It aims to showcase the very best science from collaborations between AstraZeneca and the University of Cambridge, foster inspiration and identify further areas for collaboration between the two organisations. Attendees will hear from the scientists first-hand and interact with specialists and leaders in the field.

My participation led to new potential collaboration with Astra Zeneca.
Year(s) Of Engagement Activity 2020
URL https://www.c2d3.cam.ac.uk/events/astrazeneca-and-university-cambridge-virtual-symposium
 
Description Centre33 quarterly staff meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Presentation of the project to a CPD session for Centre 33 practitioners. These engagement activities were integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project
Year(s) Of Engagement Activity 2019
 
Description Clinical Validation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Catch -up school vision screening programme : 10,000 children have missed vision screening due to Covid in Cambridgeshire - collaboration between NWAFT, CUH and CCS Trusts will enable virtual vision screening to detect vision problems and avoid resultant visual impairment.

led to clinical use within CUH and Cambridgeshire Community Trust
Plans made for future related activity
Own/Colleagues reported change in views or opinions
Audience reported changes in views, opinions or behavious
Decisions made or influenced
Reduction in avoidable sight loss in children in Cambridgeshire
Year(s) Of Engagement Activity 2021
 
Description Coeliac UK online gala dinner 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited speaker at Coeliac UK online gala dinner, November 2020
Year(s) Of Engagement Activity 2020
 
Description Coeliac disease: can we diagnose it better? 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Representing advances in coeliac disease research in the UK at the 18th International Coeliac Disease Symposium, Paris, Sept 2019
Year(s) Of Engagement Activity 2008,2019
 
Description Coral reefs, malaria and drug discovery' 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Public lecture, Cambridge Science Festival
Year(s) Of Engagement Activity 2019
 
Description Development of a Removable Transcatheter Valve as an Alternative to Surgical Valve Replacement for Aortic Stenosis 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Article in Heart Matters, the BHF magazine: Development of a Removable Transcatheter Valve as an Alternative to Surgical Valve Replacement for Aortic Stenosis
Year(s) Of Engagement Activity 2017
 
Description Development of microdialysis online-sensor technology for use in the neurocritical care of patients with acute brain injury 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Our outreach activities on critical care of acute brain trauma patients (the field to which our CiC work relates) include the following presentations:
1) Cambridge Science Festival (20.3.2016);
2) Women in Science Festival for 6th form students (Robinson College, 22.9.2016);
3)Celebrating Success in Access to HE Diploma Science (Royal Society of Chemistry, London, 4.10.2016).
Year(s) Of Engagement Activity 2016
 
Description Differentiation of human pluripotent stem cells to megakaryocytes by forward programming 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Innovative cellular approaches for transfusion medicine
Year(s) Of Engagement Activity 2019
 
Description Focus group with GPs/clinicians 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Presentation and discussion around the technology and potential usability in the clinical setting
Year(s) Of Engagement Activity 2019
 
Description Insights into Plastid evolution from dinoflagellate algae 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact NK
Year(s) Of Engagement Activity 2019
 
Description International Union of Basic and Clinical Pharmacology 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact IUPHAR reported nearly 100 international attendees with a meeting report available on the IUPHAR website.
Year(s) Of Engagement Activity 2020
 
Description Invited Speaker at MRC Centre for Regenerative Medicine, Edinburgh 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Requests for further information
Year(s) Of Engagement Activity 2020
 
Description Invited speaker at Columbia, Genetics and Development Seminar Series, New York 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited speaker at Columbia, Genetics and Development Seminar Series, New York, United States. (Virtual seminar) Requests for further information.
Year(s) Of Engagement Activity 2021
 
Description Invited speaker at IBSC virtual seminar, University of Exeter 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Invited speaker at IBSC virtual seminar, University of Exeter - Requests for further information
Year(s) Of Engagement Activity 2012,2021
 
Description Invivoscribe's European dinner, European Haematology Association, Amsterdam 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact N/A
Year(s) Of Engagement Activity 2019
 
Description Pathological Society of Great Britain and Ireland 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact n/z
Year(s) Of Engagement Activity 2019
 
Description Pharmacology December 2020 BPS 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This is the flagship BPS meeting each year. Over 1100 people registered virtually including researchers of all career stages, clinicians, publishers and teachers. Focus was to disseminate information. Outcoems have been interactions with pharma and other researchers.
Year(s) Of Engagement Activity 2006,2020
 
Description Pint of Science is an annual science festival that takes place every May and brings researchers to your local pub to show you the latest happenings in the world of science. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Pint of Science (2016): Delivered a lecture paired with optics demonstrations to illustrate novel endoscopic imaging to the public
Year(s) Of Engagement Activity 2016
URL https://pintofscience.co.uk/
 
Description Pint of Science presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Development of a Removable Transcatheter Valve as an Alternative to Surgical Valve Replacement for Aortic Stenosis
Year(s) Of Engagement Activity 2017
 
Description RSC Emerging Technologies Competition 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact The University of Cambridge has developed a new class of therapeutic metalloproteins that allows controlled and targeted delivery of carbon monoxide into tumours. The compounds, developed by Gonçalo Bernardes, led to strong immune-mediated tumour growth retardation in tumour-bearing mice.
Gonçalo Bernardes was awarded the 2nd prize in Healthcare
Year(s) Of Engagement Activity 2015
 
Description RadNet Steering Committee meeting 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact RadNet Steering Committee meeting. The study was chosen to present as a collaboration piece for the CRUK RadNet network. The most important impact was to get agreement from all 6 CRUK RadNet centres to join the study.
Year(s) Of Engagement Activity 2020
 
Description SBC news article 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Industry/Business
Results and Impact The confidential nature of our data limits further engagement at the moment
Year(s) Of Engagement Activity 2019,2020
 
Description Sensors Day 2018 "Design and Development of Mid-infrared Optical Sensors". 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Farah Alimagham also attended Sensors Day 2018, 10 October 2019, Fitzwilliam College, Cambridge (conference organised by the Sensor CDT), where she presented a poster entitled: "Design and Development of Mid-infrared Optical Sensors". It was very general and included continuous biofluid monitoring (as a general topic), bioreactor monitoring, and the use of meta materials for high-sensitivity chemical sensing.
Year(s) Of Engagement Activity 2018
 
Description Sensors in Medicine 2019, London 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact At Sensors in Medicine 2019 (see above), Farah Alimagham presented a poster featuring our sensor. The title was "Mid-IR Sensor Systems & Devices for Medical Diagnostics and Monitoring" and the authors were Farah Alimagham, Tanya Hutter, Keri Carpenter, Peter Hutchinson, and Stephen R Elliott. This won Best Poster prize.
Year(s) Of Engagement Activity 2019
 
Description Soapbox Science (2016): Stood on a soapbox in Cambridge Market Square 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Other audiences
Results and Impact Stood on a soapbox in Cambridge Market Square explaining the concepts of wavelength and polarization, illustrating how they might be used in diagnosis of cancer.
Year(s) Of Engagement Activity 2016
URL http://soapboxscience.org/soapbox-science-2016-cambridge/
 
Description Targeted delivery of CO using artificial metalloproteins: CO's immunomodulatory properties for cancer therapy 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact "Targeted delivery of CO using artificial metalloproteins: CO's immunomodulatory properties for cancer therapy". Presentation about the technology "artificial metalloproteins for targeted delivery of CO in cancer therapy" at the RSC Emerging Technologies Competition 2015 (awarded the 2nd prize in Healthcare)
Year(s) Of Engagement Activity 2015
 
Description The 11th International Retroviral Nucleocapsid and Assembly Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact The IRNCAS meeting is the The 11th International Retroviral Nucleocapsid and Assembly Symposium held in North Eastern University in Boston and was an international science conference with scientists in the audience from all parts of the world
Year(s) Of Engagement Activity 2019
 
Description The NIHR Applied Research Centre (ARC) East of England 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact These engagement activities are integral to the development of the app but also for informing plans to for how it would successfully be applied within secondary schools for the next stage of the project
Year(s) Of Engagement Activity 2021
 
Description University of Cambridge Primary School - "We are Scientists" 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact University of Cambridge Primary School: Our school outreach talk was part of an online event called "We are Scientists" at the University of Cambridge Primary School, which took place on 9th Nov 2020. Our talk was titled "We are Neuroscientists: studying the brain". It was a pre-recorded slide presentation with narration, followed by a live (via Microsoft Teams) Q&A session in which the audience of school-children asked us questions. The audience was local, approx. 60 staff and pupils. This talk is now on YouTube.
Year(s) Of Engagement Activity 2020
 
Description University of Cambridge Virtual Summer Festival of Learning "Neuroscience: unravelling the brain" 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact We achieved success with our pre-recorded talk, titled "Neuroscience: unravelling the brain" narrated by Prof Hutchinson, which was part of the University of Cambridge Virtual Summer Festival of Learning online programme (6th-24th July 2020), which was an international event. Ours was in the Free Open Talks section, free-to-access by members of the public - our talk had 190 views. This talk is now on YouTube.
Year(s) Of Engagement Activity 2020
 
Description Workshop for the Institute of Physics, CamAWiSE, and Schlumberger Gould Research Center 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Novel Imaging for Cancer
Year(s) Of Engagement Activity 2015
URL https://camawise.org.uk/2015/10/16/novel-imaging-for-cancer-dr-sarah-bohndiek-by-raheela-rehman/
 
Description the manufacturing of blood cells in vitro 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact generated a movie to answer these questions_this has been distributed through YouTube (1.5k views) and Tweeter (via the Cambridge Stem Cell Institute_>20,000 hits
Year(s) Of Engagement Activity 2020